Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636470 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL20878382 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL18636473 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL22096278 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL18636467 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL18667331 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9KRASBTN3A1RIPK1 | |
| SCHEMBL25012467 | 0.94 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL24975049 | 0.94 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL18636485 | 0.94 | CYP3A4 (0.40) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL23661284 | 0.93 | CYP3A4 (0.37) | CYP3A4CYP2C9KRASBTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207291-A1 | METHODS FOR TREATING POXVIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | GILEAD SCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11701372-B2 | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10695357-B2 | Methods for treating filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | EIF2AK2, MTAP, ACE | CYP3A4 628/4885CYP2C9 879/4885KRAS 1899/4885 |
| US-10695357-B2 | Methods for treating filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-11701372-B2 | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs | SLC29A1, SLC28A1, SLC29A2 | CYP3A4 1147/4885CYP2C9 633/4885KRAS 2235/4885 |
| US-20240207291-A1 | METHODS FOR TREATING POXVIRUS INFECTIONS | VAC14, SDHB, XDH | CYP3A4 3182/4885CYP2C9 3880/4885KRAS 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.